Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 50.0-80.0,  Emphysema Candidates for this study must meet all of the following 1. Patient between 50 to 80 years old 2. High Resolution CT scan indicates homogeneous or heterogeneous emphysema. 3. Patient has post bronchodilator FEV1 less than or equal to 45% of predicted 4. Total Lung Capacity > 100% of predicted. 5. Residual volume≥ 200% of predicted. 6. Patient has marked dyspnea scoring >2 on mMRC scale of 0-4. 7. Patient has stopped smoking for a minimum of 8 weeks prior to entering the study, as confirmed by COHb ≤2.5% 8. Patient (and legal guardian if applicable) read, understood and signed the Informed Consent form. 9. Subject has completed a pulmonary rehab within the last year and/or performs regularly physical activity. Candidates will be excluded from the study if any of the following conditions are present: 1. Patient has a change in FEV1 > 20% post-bronchodilator 2. Patient has a history of recurrent clinically significant respiratory infection, defined as with more than 3 hospital stays in the past 12 months. 3. Patient has uncontrolled pulmonary hypertension defined by right ventricular pressure>50mmHg and/or evidenced by echocardiogram. 4. Patient has an inability to walk >140 meters (150 yards) in 6 minutes. 5. Patient has evidence of any other disease that may compromise survival such as lung cancer, renal failure, any other investigator identified such evidences. 6. Patient is pregnant or lactating. 7. Patient has an inability to tolerate bronchoscopy under anesthesia. 8. Any contraindication to bronchoscopy procedure, including but not limited to: 1. Untreatable life-threatening arrhythmias 2. Inability to adequately oxygenate the patient during the procedure 3. Acute respiratory failure with hypercapnia 4. Within 6 months myocardial infarction 5. Previously diagnosed high-grade tracheal obstruction 6. Uncorrectable coagulopathy 9. Patient has clinically significant bronchiectasis. 10. Patient has giant bullae > 1/3 lung volume. 11. Patient has had previous LVR surgery, lung transplant or lobectomy，or has still ELVR devices or other device to treat COPD in either lung. 12. Patient has been involved in other clinical studies within 30 days prior to this study. 13. Patient is taking > 20mg prednisone (or similar steroid) daily. 14. Patient on antiplatelet agent (eg, clopidogrel) or anticoagulant therapy (eg, heparin or coumadin) or has not been weaned off prior to procedure. 15. Patient has any other disease that would interfere with completion of study, follow up assessments or that would adversely affect outcomes. 16. A known allergy to nitinol. 17. Patient with uncontrolled diabetes as well as overweight patient (BMI > 35 kg/m2) 18. Cancer needs chemotherapy in past two years 19. Patient with pleural effusion and/or pneumothorax 20. Patient with a disease history of asthma, cystic fibrosis, interstitial lung disease (ILD), active tuberculosis; 21. Patient with exacerbation of chronic obstructive pulmonary disease (COPD) which defined as: An acute event with the need of antibiotic treatment or hospitalization. 22. Subject has severe gas exchange abnormalities as defined by: PaCO2 >55 mm Hg,PaO2 <45 mm Hg on room air 23. Patient with acute ischemic heart disease, with proven pulmonary hypertension (SPAP> 45 mmHg) in echocardiography and/or need for double platelet aggregation inhibition